SAGE Therapeutics Inc. (SAGE)

139.79
NASDAQ : Health Technology
Prev Close 136.46
Day Low/High 134.11 / 139.90
52 Wk Low/High 79.88 / 195.97
Avg Volume 552.80K
Exchange NASDAQ
Shares Outstanding 46.89M
Market Cap 6.40B
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

SAGE Therapeutics Soars on Promising Postpartum Drug-Trial Results

Stock doubles in value on positive Stage 3 trial results showing "meaningful" treatment of postpartum depression symptoms.

Sage Therapeutics To Provide Update On Key 2019 Initiatives At J.P. Morgan Healthcare Conference

Sage Therapeutics To Provide Update On Key 2019 Initiatives At J.P. Morgan Healthcare Conference

Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Chief Executive Officer, Jeff Jonas, M.

Sage Therapeutics Announces SAGE-217 Meets Primary And Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression

Sage Therapeutics Announces SAGE-217 Meets Primary And Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression

Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from the Phase 3 ROBIN Study.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2019, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 8, 2019

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 8, 2019

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the J.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 3, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Piper Jaffray 30th Annual Healthcare Conference

Sage Therapeutics To Present At Piper Jaffray 30th Annual Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30 th Annual...

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO™ (brexanolone) Injection

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Notable Tuesday Option Activity: SAGE, REN, TSLA

Notable Tuesday Option Activity: SAGE, REN, TSLA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 4,861 contracts have traded so far, representing approximately 486,100 underlying shares. That amounts to about 101.3% of SAGE's average daily trading volume over the past month of 479,955 shares.

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics To Present At Stifel 2018 Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Stifel 2018 Healthcare Conference...

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Third Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the third quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on November 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 In Support Of Benefit-Risk Profile Of ZULRESSO™ (brexanolone) Injection For Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO™ (brexanolone) Injection For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that NASDAQ has halted trading of the company's common stock.

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Sage Therapeutics Turned Down - Don't Rush to Be a Buyer

Let's see what the charts and indicators look like.

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Red Hat, Take-Two Interactive, Sage Therapeutics: 'Mad Money' Lightning Round

Jim Cramer weighs in on Red Hat, Take-Two Interactive, Sage Therapeutics, Mazor Robotics, Donnelly Financial Solutions.

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Untangling the Spin: Cramer's 'Mad Money' Recap (Thursday 10/25/18)

Jim Cramer says investors need context about what's really happening with earnings, tariffs, the Fed, and in Washington.

Noteworthy Wednesday Option Activity: SAGE, BERY, LOB

Noteworthy Wednesday Option Activity: SAGE, BERY, LOB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 1,657 contracts has been traded thus far today, a contract volume which is representative of approximately 165,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42% of SAGE's average daily trading volume over the past month, of 394,205 shares.

Sage Therapeutics To Report Third Quarter 2018 Financial Results On Tuesday, November 6, 2018

Sage Therapeutics To Report Third Quarter 2018 Financial Results On Tuesday, November 6, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Sage Therapeutics To Present At Morgan Stanley 16th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Morgan Stanley 16th Annual Global...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on September 4, 2018, the Compensation Committee of Sage's Board...

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics Announces The Lancet Publishes Integrated Data From Pivotal Trials For Brexanolone Injection In Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced The Lancet has published an integrated analysis across three,...

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics Announces Second Quarter 2018 Financial Results And Highlights Pipeline And Business Progress

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and financial results for the second quarter...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on August 1, 2018, the Compensation Committee of Sage's Board of...

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics To Present At Canaccord 38th Annual Growth Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth...

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics To Report Second Quarter 2018 Financial Results On Tuesday, August 7, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage's Board of...